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A b s t r a c t
Background: Decreased lung function is related to higher cardiovascular disease (CVD) incidence and mortality. However, 
little is known about the relationship between the risk factors of CVD and pulmonary function.
Aim: The aim of the study was to assess the relationship between the prevalence of cardiovascular risk factors, the total CVD 
risk, and pulmonary function. 
Methods: The analysis included 4104 men and women aged 45 to 69 years, participants of the Polish part of the Health, Alcohol, 
and Psychosocial factors In Eastern Europe (HAPIEE) Project, who provided valid measurements of forced expiratory volume 
in one second (FEV1) and forced vital capacity (FVC) using a Micro-Medical Microplus spirometer. The prevalence of CVD risk 
factors was defined as follows: hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or 
taking hypertension medication), diabetes (glucose ≥ 7.1 mmol/L or self-reported diabetes), and hypercholesterolaemia (total 
cholesterol ≥ 5 mmol/L or low-density lipoprotein-cholesterol ≥ 3 mmol/L or taking lipid lowering medication). Categories of 
total CVD risk were defined according to the 2016 European Guidelines on CVD prevention in clinical practice. The analysis 
of covariance was used to compare the lung function in the CVD risk factors and the total CVD risk categories. 
Results: Mean values of FEV1 and FVC, adjusted for age and height, were significantly higher in men than in women (3.02 L; 
95% confidence interval [CI] 2.96–3.08 L vs. 2.52 L; 95% CI 2.45–2.63 L for FEV1 and 3.62 L; 95% CI 3.56–3.69 L vs. 3.05 L; 
95% CI 2.98–3.12 L for FVC). Obesity was significantly associated with FVC in men and women; it was associated with FEV1 only 
in men. Compared with participants with normal body mass index, obese men and women had 280 mL and 112 mL lower 
mean FVC, respectively. Men without hypertension had almost 100 mL higher mean FVC than those with hypertension. The 
difference in FVC in women was approximately 80 mL. Diabetes was associated with lower values of FVC in both sexes and with 
FEV1 in women. A significant negative trend was observed in the mean FVC and FEV1 by the considered CVD risk categories. 
Conclusions: Impaired lung function was associated with higher CVD risk, which could be explained partly by an adverse 
association between lung function and prevalence of obesity, hypertension, and diabetes.
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INTRODUCTION
In clinical practice, pulmonary function measurement is usu-
ally used for identifying persons with airway obstruction or 
other ventilatory defects. The assessment includes spirometry, 
which results in outcomes such as forced expiratory volume 
in one second (FEV1) and forced vital capacity (FVC). Persons 
with results lower than the predicted values, calculated from 
the measurements of the reference groups (according to 
age, sex, and height), are considered to have low pulmonary 
function [1].
Lung function parameters can be used for predicting 
morbidity and mortality [2]. Besides association with chronic 
obstructive pulmonary disease (COPD) and lung cancer [2], 
low pulmonary function was found to be related to cardio-
vascular disease (CVD) [3], coronary artery disease [2], atrial 
fibrillation [4], diabetes [5], and other disadvantageous con-
ditions such as obesity [5], hypertension [6], high low-den-
sity lipoproteins (LDLs), and low high-density lipoproteins 
(HDLs) [7]. Pulmonary dysfunction has been found in persons 
with metabolic syndrome and diabetes [5], asthma [8], and 
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lung disease [9]. Reports of pulmonary function assessment 
in the general population are not very extensive [10, 11]. 
Moreover, the relationship between pulmonary function and 
CVD risk factors has thus far been assessed for separate risk 
factors [5–7, 12], while evidence of the relationship between 
lung function and the combined effect of CVD risk factors, 
i.e. total CVD risk in the same individuals, is scarce [3, 13]. 
Therefore, the aim of the present study was to assess the 
relationship between the prevalence of cardiovascular risk 
factors, the total CVD risk, and pulmonary function. 
METHODS
The analysis was performed using data from the Polish part 
of the Health, Alcohol, and Psychosocial factors In Eastern 
Europe (HAPIEE) Project, which is described in detail else-
where [14]. A brief summary relevant to the present analysis 
is given below. The HAPIEE Project involved a random 
sample of Kraków residents aged between 45 and 69 years 
at the baseline. Trained nurses interviewed respondents in 
their homes. Information on age, education, marital status, 
employment status, health status (history of CVD, asthma, hy-
pertension, diabetes, and hypercholesterolaemia), and health 
behaviours (smoking and physical activity) was obtained using 
a standard questionnaire. Then, all participants were invited 
to the clinic for anthropometric and blood pressure (BP) 
measurements followed by blood collection for biochemical 
tests, and subsequent spirometry. Height and weight were 
measured in the vertical position by using electronic scales 
with a built-in ruler in participants wearing light indoor cloth-
ing and no shoes. 
Physical activity measurement was based on the ques-
tion “How many hours during a typical week do you engage 
in sports, games, or hiking?” Participants’ responses were 
categorised according to the guidelines of the World Health 
Organisation. The recommended physical activity was defined 
as at least 150 min of moderate-intensity aerobic physical 
activity throughout the week, and poor if more than 0 min but 
less than 150 min per week. Furthermore, a participant was 
defined as an inactive person when the time of physical activ-
ity was 0. The body mass index (BMI) was calculated as weight 
in kilograms divided by the square of height in metres. In the 
analysis, we included participants with BMI ≥ 18.5 kg/m2. The 
smoking status was coded as current, former, or never-smoker. 
Hypertension was defined as systolic BP (SBP) ≥ 140 mmHg 
and/or diastolic BP (DBP) ≥ 90 mmHg, or when the participant 
was on medication for hypertension. Diabetes was categorised 
as either self-reported diabetes (defined as self-reported history 
of diabetes or use of hypoglycaemic medication) or detected 
diabetes (defined as fasting serum glucose level ≥ 7.0 mmol/L). 
A participant was considered to have hypercholesterolaemia 
if his/her total cholesterol (TC) level was ≥ 5.0 mmol/L, his/her 
LDL cholesterol (LDL-C) level was ≥ 3.0 mmol/L, or he/she 
was on lipid-lowering medication.
The 10-year risk of fatal CVD (SCORE risk) was calcu-
lated using the algorithm for high-risk countries [15], which 
included the participants’ age, sex, smoking status, TC level, 
and SBP. SCORE was calculated for participants who did not 
report a history of diabetes mellitus, myocardial infarction, or 
stroke at the baseline health assessment, and for individuals 
who required a complete dataset on CVD risk factors. SCORE 
was categorised as low or moderate (SCORE < 5%), high 
(5% ≤ SCORE < 10%), and very high (SCORE ≥ 10%). Based 
on information about heart attack/acute myocardial infarc-
tion, stroke, diabetes, smoking status, prevalence of CVD 
risk factors, and the SCORE value, the total CVD risk for 
each participant was estimated according to the European 
Guidelines on Cardiovascular Disease Prevention in Clinical 
Practice (version 2016) [16].
Pulmonary function assessment 
Pulmonary function was assessed in a randomly selected 
part of the studied sample. In the current study, we used two 
measures: FVC and FEV1, which were measured by a trained 
technician in accordance with a standardised protocol [17], 
using a Microplus (Micro-Medical Ltd., Rochester, United 
Kingdom) spirometer. Subjects performed spirometry in the 
standing position with a nose clip in place. They were asked 
to make at least three maximal expiratory manoeuvres. The 
highest values of FVC and FEV1 were chosen from meas-
urements that met the acceptability criteria of satisfactory 
and repeatability exhalation [17]. Furthermore, before the 
spirometric examination, the participants were interviewed 
on their current health status (any surgery within the three 
months preceding the examination or the use of an inhaler 
for asthmatic patients), as well as their current smoking and 
drinking behaviours. 
Statistical analysis 
Descriptive statistics were calculated according to sex as 
means and standard deviations for pulmonary function param-
eters and as the prevalence rate for categorical variables. To 
compare the FVC and FEV1 distributions for classical CVD risk 
factors and the category of total CVD risk, an analysis of covari-
ance was performed. All analyses were performed separately 
for men and women. Interactions between age and education 
level and the considered risk factors were verified; however, 
because these interactions were not statistically significant, 
they were not included in the final model. The final model 
was adjusted for age, height, education level, physical activ-
ity (categorical variable), smoking status, smoking frequency 
(pack-years), and the prevalence of respiratory diseases 
(yes/no). Moreover, because of the strong association be-
tween smoking and lung function, the models were repeated 
with stratification by smoking status. The c2 test was used to 
compare the distribution of CVD risk factors between men 
and women and between participants who were included 
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in the analysis and those who were excluded. Data were 
analysed using Statistical Package for the Social Sciences 
(SPSS) version 22.0 (SPSS Inc., Armonk, NY, USA). All tests 
were two-tailed, p-value less than 0.05 was considered 
statistically significant. 
RESULTS
Out of the 4840 participants who performed spirometry, 
4104 (84.4%) completed adequate lung function measure-
ment. Those who were unable to complete the measurement 
were more likely to be smokers (34% vs. 26%, p = 0.043) 
and had a higher prevalence of respiratory diseases (18% 
vs. 13%, p = 0.003). No significant difference in sex, age, 
and prevalence of CVD risk factors between these two groups 
was observed. 
Descriptive statistics of the studied group are presented 
in Table 1. The mean age was 55.6 ± 6.92 years; men 
were slightly older than women (57.9 years vs. 57.2 years, 
p < 0.001). The mean FEV1 adjusted for age and height was 
significantly higher in men than in women (3.02 L; 95% 
confidence interval [CI] 2.96–3.08 L vs. 2.52 L; 95% CI 
2.45–2.63 L). The mean FVC adjusted for age and height was 
3.25 L (95% CI 3.22–3.28 L); the difference in the mean FVC 
between men and women was 0.57 L and was statistically 
significant: 3.62 L (95% CI 3.56–3.69 L) and 3.05 L (95% CI 
2.98–3.12 L), respectively. No differences were observed in 
the prevalence of respiratory disease and physical activity 
levels between men and women. The prevalence of CVD risk 
factors differed between sexes. Men smoked more frequently 
than women. Furthermore, a greater number of men had 
hypertension and diabetes than women, while the prevalence 
of obesity and hypercholesterolaemia was higher in women. 
The SCORE risk value was calculated for 2889 participants 
(excluding those with a history of diabetes mellitus, myocar-
dial infarction, and/or stroke). The proportion of participants 
with a very high risk (SCORE ≥ 10) was approximately seven 
Table 1. Descriptive statistics of the studied group
Men (n = 2020) Women (n = 2084) p
Age [years] 57.91 ± 6.86 57.2 ± 7.00 0.001
University level of education 609 (30.2%) 539 (25.9%) 0.002
Respiratory disease 266 (13.2%) 285 (13.7%) 0.7
Physical activity: 0.7
Inactive 523 (26.9%) 525 (26.5%)
Poor 236 (12.1%) 226 (11.4%)
Recommended 1185 (61.0%) 1228 (62.1%)
BMI: < 0.001
Normal 430 (21.6%) 542 (26.7%)
Overweight 1001 (49.8%) 807 (38.8%)
Obesity 575 (28.6%) 716 (34.5%)  
Smoking status: < 0.001
Current 666 (33.1%) 539 (25.9%)
Former 755 (37.5%) 419 (20.2%)
Never 592 (29.4%) 1121 (53.9%)  
Hypertension 1344 (67.1%) 1115 (53.8%) < 0.001
Diabetes 337 (16.7%) 270 (13.0%) 0.001
Hypercholesterolaemia 1694 (84.2%) 1807 (87.0%) 0.01
SCORE risk category: < 0.001
Low or moderate 597 (43.7%) 1291 (86.0%)  
High 437 (32.0%) 160 (10.7%)
Very high 333 (24.4%) 51 (3.4%)
CVD risk category: < 0.001
Low or moderate 576 (28.7%) 1239 (60.0%)
High 462 (23.1%) 216 (10.5%)
Very high 966 (48.2%) 611 (29.6%)
Data are shown as mean ± standard deviation or number (percentage). BMI — body mass index; CVD — cardiovascular disease
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times higher in men than in women. The percentage of men 
in the very high total CVD risk category was approximately 
63% higher than that of women. 
Results of the analyses of the relationship between the dif-
ferent CVD risk factors and CVD risk categories and lung func-
tion are presented in Tables 2 and 3, respectively. Obesity was 
significantly associated with FVC in men and in women, but 
the relationship between obesity and FEV1 was significant only 
in men. Compared with that of the participants with normal 
BMI, the FVC of men and women with obesity was 280 mL 
and 112 mL lower, respectively. Both FEV1 and FVC were 
strongly related to hypertension. Men free of hypertension 
had 93 mL higher mean FVC than those with hypertension. 
The difference in FVC in women was approximately 80 mL. 
Diabetes was significantly and inversely associated with FVC in 
both sexes and with FEV1 in women. The adjusted difference 
in mean FVC in women was approximately 90 mL, and it was 
155 mL in men. Hypercholesterolaemia was not significantly 
related with FEV1 and FVC. A significant negative trend was 
observed in the mean FVC and FEV1 in both sexes for the total 
CVD risk categories. Compared with participants with low or 
moderate risk, men with a very high CVD risk had a relatively 
low mean FVC of approximately 180 mL; women had a mean 
FVC of approximately 110 mL (Figs. 1, 2). 
After stratification by smoking status, the results were 
similar to those obtained in the pooled analysis. Tables 4 and 5 
present the relationship between FEV1, FVC, and the different 
CVD risk factors and CVD risk categories in the never-smokers 
and in the current or former smokers. Lung function was 
naturally worse in the current and former smokers; however, 
besides the relationship between FEV1 and hypertension 
and FVC and a few of the risk factors (BMI, hypertension, 
diabetes, and CVD risk) in smoking women, other associa-
tions that were significant in the pooled analysis remained 
significant in the never-smokers and in the current or former 
smokers. Restriction of the group only to the current smokers 
did not substantially change the results.
DISCUSSION
In the current study, we observed a relationship between 
pulmonary function and CVD risk factors such as obesity, 
hypertension, and diabetes and pulmonary function; however, 
a relationship between hypercholesterolaemia and pulmonary 
function was not found. The results obtained in the group of 
never-smokers showed the same pattern, although it was not 
significant in the case of hypertension, probably because of 
the relatively small number of participants and insufficient 
statistical power. Furthermore, a relationship between both 
FEV1 and FVC, and CVD risk categories was observed in the 
study. These results are similar to those obtained by other 
researchers [3, 5, 6], although the mean value of spirometric 
parameters obtained in our study differed slightly from the 
Table 2. Relationship between forced expiratory volume in one second (FEV1) and cardiovascular disease (CVD) risk factors and 
total CVD risk
  Men Women
  n Mean* [cL] 95% CI p n Mean* [cL] 95% CI  p
BMI: < 0.001 0.06
Normal 427 305.86 300.4–311.3 547 218.50 214.8–222.2
Overweight 983 306.60 302.5–310.7 797 219.87 216.6–223.4
Obesity 564 290.15 258.3–295.0 705 215.35 212.0–218.7
Hypertension: 0.01 0.001
No 310 305.20 300.3–310.1 947 219.89 216.6–223.2
Yes 1664 298.96 294.8–303.1 1095 214.14 210.9–217.4
Hypercholesterolaemia: 0.2 0.25
No 274 297.49 291.1–303.9 267 214.79 209.8–219.8
Yes 1523 301.88 297.9–305.8 1781 217.62 214.7–220.5
Diabetes: 0.1 0.03
No 1646 302.16 298.2–306.1 1782 217.89 215.0–220.7
Yes 330 297.05 290.9–303.2 263 212.40 207.3–217.5
CVD risk category: 0.01 < 0.001
Low or moderate 570 305.75 300.0–311.5 1230 220.57 217.4–223.7
High 456 303.74 298.0–309.4 215 215.85 210.2–221.5
Very high 947 297.32 292.7–301.9   598 211.48 207.7–215.2
*Obtained by analysis of covariance, adjusted for age, height, education level, physical activity, smoking status, smoking frequency, and the  
prevalence of respiratory diseases; BMI — body mass index; cL — centilitres; CI — confidence interval
www.kardiologiapolska.pl
Maciej Polak et al.
1058
Table 3. Relationship between forced vital capacity (FVC) and cardiovascular disease (CVD) risk factors and total CVD risk
  Men Women
  n Mean* [cL] 95% CI p  n Mean* [cL] 95% CI  p
BMI: < 0.001 < 0.001
Normal 382 384.5 377.9–391.0 513 273.7 269.3–278.1
Overweight 889 375.1 370.1–380.0 752 269.9 266.1–273.7
Obesity 525 356.5 350.7–362.3 658 262.5 258.5–266.4
Hypertension: 0.002 < 0.001
No 578 378.0 372.0–383.9 881 271.6 267.8–275.5
Yes 1214 368.7 363.8–373.7 1039 264.0 260.3–267.8
Hypercholesterolaemia: 0.3 0.99
No 274 368.0 360.3–375.7 248 267.8 261.9–273.7
Yes 1523 372.1 367.4–376.8 1678 267.8 264.5–271.2
Diabetes: < 0.001 0.002
No 1495 374.6 369.8–379.3 1679 268.9 265.5–272.2
Yes 305 359.1 351.7–366.5 244 259.9 253.8–265.9
CVD risk category: < 0.001 < 0.001
Low or moderate 517 382.8 375.9–389.7 1161 271.4 267.8–275.1
High 427 371.2 364.4–377.9 195 268.4 261.6–275.1
Very high 851 365.1 359.5–370.7   563 260.6 256.2–265.0
*Obtained by covariance, adjusted for age, height, education level, physical activity, smoking status, smoking frequency, and the prevalence of 
respiratory diseases. Abbreviations — see Table 2
Figure 1. Mean value of forced expiratory volume in one se-
cond (FEV1) in categories of total cardiovascular disease (CVD) 
risk by sex Figure 2. Mean value of forced vital capacity (FVC) in catego-
ries of total cardiovascular disease (CVD) risk by sex
other populations. However, it should be taken into account 
that direct comparison of FVC and FEV1 may be difficult due 
to the different age range of the studied groups. If the com-
parison is limited to the studies that included participants of 
similar age, the mean FVC and FEV1 obtained in the current 
study were lower compared to Polish part of the BOLD study 
(which included populations of Chrzanów and Proszowice) 
and to the Italian study that involved 8000 participants. It is 
likely that worse pulmonary function in residents of Kraków 
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could be explained by air pollution and a higher smoking 
rate [12, 18].
The underlying mechanism of the relationship between 
pulmonary function and CVD risk factors is unclear, except 
for smoking, which may affect respiratory functioning and 
increase the CVD risk. The inflammation process was sug-
gested to be involved in this mechanism. For example, it has 
been found that metabolic syndrome, which causes inflam-
mation in the lungs, may influence the further occurrence of 
lung function impairment [19]. It has also been observed that 
systemic inflammation in participants with airflow obstruc-
tion could be associated with an increased risk of cardiac 
injury [20]. COPD, characterised by disabled lung function, 
is associated with systemic inflammation, and an increased 
risk of CVD was observed in patients with COPD. The gly-
cosylation of protein (such as collagen in the lungs and the 
chest wall) may also play a role in the relationship between 
diabetes and impaired lung function. Decreased lung func-
tion observed among diabetic patients may be explained by 
collagen accumulation in the lung connective tissue [21]. 
Respiratory impairment among persons with diabetes might 
be influenced by increased BMI and result in fat deposits 
between the muscles and the ribs, which decrease chest wall 
compliance and weaken the respiratory muscles [22]. Other 
researchers have suggested that some processes that may lead 
to CVD risk factors (such as alterations in arterial functions) 
may share similar physiopathological pathways as those that 
result in impaired respiratory function, but the nature of these 
relationships remains unknown [23].
We may assume that the inverse relationship between 
lung function and CVD risk categories was a result of the fact 
that the CVD risk categories were based on several risk factors 
(diabetes, hypertension, etc.), which were directly related to 
impaired lung function.
This study has several limitations that need to be con-
sidered when interpreting the results. First, the data were 
collected in a cross-sectional manner, which made the as-
sessment of the direction of the relationship difficult and did 
not allow us to conclude a cause-effect relationship. There 
are suggestions in both directions of the relationship between 
pulmonary function and CVD risk. Poor pulmonary function 
may influence the further development of CVD risk factors 
[24]. On the other hand, exposure to CVD risk factors may 
trigger the further dysfunction of lungs [19]. Second, although 
we examined a part of the random population sample, this 
sample consisted of citizens of a large Polish city and was not 
representative of the entire Polish population. Moreover, the 
examinations were performed on the healthier part of the 
population because of the low participation rate [25]. How-
ever, this issue was addressed by another analysis, in which 
we compared a sample of participants that had undergone 
spirometry with the entire sample of the HAPIEE Project; this 
other analysis showed that no difference in the two groups was 
observed on the prevalence of CVD risk factors (not discussed 
in the ‘Results’ section). Moreover, our previous findings re-
vealed that the HAPIEE respondents did not differ from the 
population of other large Polish towns for the classic risk fac-
tors [26]. Another limitation may be related to the SCORE risk 
assessment; in the analysis, we used an algorithm for high-risk 
countries, which was developed in 2003 [15]; however, in 
the Polish HAPIEE sample, this approach overestimated the 
10-year mortality [27]. In 2015, a new system of CVD risk 
assessment in Poland called Pol-SCORE was developed and 
recalibrated [28], but we decided to use the first of these two, 
because the data on spirometry and CVD risk factors were 
collected between 2002 and 2005. 
A less important limitation of our study, as related only 
to one covariate, could be that assessment of physical activity 
was based only on one self-reported question. In our study the 
percentage of participants who had the recommended level of 
physical activity was higher compared to findings of other Polish 
population-based studies, i.e. NATPOL and WOBASZ [29–31].
Despite the limitations, there are some advantages of the 
current study. We used the data collected from a large random 
sample of Kraków citizens and the variables of interest were 
measured using standardised methods. Pulmonary function 
was measured in accordance with the recommendations of 
European Respiratory Society [17], CVD risk factors were de-
fined according to the European Guidelines on Cardiovascular 
Disease Prevention in Clinical Practice [16], and other mea-
surements were collected using a standardised questionnaire.
In conclusion, impaired lung function was associated with 
higher CVD risk, which  could be explained partly by adverse 
association between lung function and prevalence of obesity, 
hypertension, and diabetes.
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